The use of a lactic acid gel in the treatment and prevention of bacterial vaginosis and urinary tract infections as a challenge to antibacterial therapy. A literature review

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Bacterial vaginosis and urinary tract infections are common conditions that lead to a decrease in the quality of life and significant economic costs. The review provides up-to-date information on the role of lactic acid in the microbiota of the vagina and urinary tract, as well as on the use of a lactic acid gel in these conditions. Bacterial vaginosis is associated with an increased risk of urinary tract infections. Antibacterial therapy demonstrates statistically significant results in treating exacerbation, but not preventing further relapses, which is due to the possible high ability of bacteria to form biofilms. Lactic acid, unlike hydrogen peroxide, is involved in maintaining the vaginal microbiota and enhancing its protective function against sexually transmitted infections, and indirectly affects the urinary microbiota. This may allow the use of lactic acid for the treatment and prevention of relapses in both bacterial vaginosis and urinary tract infections.

Full Text

Restricted Access

About the authors

Alena D. Minakova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: alenami1205@yandex.ru
ORCID iD: 0000-0002-5157-1888
SPIN-code: 6649-7776

MD, PhD student

Russian Federation, Moscow

Tea A. Dzhibladze

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: djiba@bk.ru
ORCID iD: 0000-0003-1540-5628
SPIN-code: 5688-1084
Scopus Author ID: 57194218506

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Vladimir M. Zuev

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: vlzuev@bk.ru
ORCID iD: 0000-0001-8715-2020
SPIN-code: 8725-1419
Scopus Author ID: 7201884764

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Irina D. Khokhlova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: irhohlova5@gmail.com
ORCID iD: 0000-0001-8547-6750
SPIN-code: 6858-5235
Scopus Author ID: 57194137494

MD, Cand. Sci. (Med.), Assistant Professor

Russian Federation, Moscow

References

  1. Diop K, Dufour J-C, Levasseur A, et al. Exhaustive repertoire of human vaginal microbiota. Hum Microbiome J. 2019;11. doi: 10.1016/j.humic.2018.11.002
  2. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA. 2011;108(Suppl. 1):4680–4687. doi: 10.1073/pnas.1002611107
  3. De Seta F, Campisciano G, Zanotta N, et al. The vaginal community state types microbiome-immune network as key factor for bacterial vaginosis and aerobic vaginitis. Front Microbiol. 2019;10. doi: 10.3389/fmicb.2019.02451
  4. Amabebe E, Anumba DOC. The vaginal microenvironment: the physiologic role of Lactobacilli. Front Med (Lausanne). 2018;5:181. doi: 10.3389/fmed.2018.00181
  5. Peebles K, Velloza J, Balkus JE, et al. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sex Transm Dis. 2019;46(5):304–311. doi: 10.1097/OLQ.0000000000000972
  6. Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478–1486. doi: 10.1086/503780
  7. Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 2005;106(5 Pt 1):1013–1023. doi: 10.1097/01.AOG.0000183594.45524.d2
  8. Swidsinski A, Mendling W, Loening-Baucke V, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol. 2008;198(1):97.e1–97.e976. doi: 10.1016/j.ajog.2007.06.039
  9. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2(2):95–108. doi: 10.1038/nrmicro821
  10. Tenke P, Köves B, Nagy K, et al. Update on biofilm infections in the urinary tract. World J Urol. 2012;30(1):51–57. doi: 10.1007/s00345-011-0689-9
  11. Patterson JL, Girerd PH, Karjane NW, et al. Effect of biofilm phenotype on resistance of Gardnerella vaginalis to hydrogen peroxide and lactic acid. Am J Obstet Gynecol. 2007;197(2):170.e1–170.e1707. doi: 10.1016/j.ajog.2007.02.027
  12. Cherpes TL, Hillier SL, Meyn LA, et al. A delicate balance: risk factors for acquisition of bacterial vaginosis include sexual activity, absence of hydrogen peroxide-producing lactobacilli, black race, and positive herpes simplex virus type 2 serology. Sex Transm Dis. 2008;35(1):78–83. doi: 10.1097/OLQ.0b013e318156a5d0
  13. Fethers KA, Fairley CK, Hocking JS, et al. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin Infect Dis. 2008;47(11):1426–1435. doi: 10.1086/592974
  14. Bhakta V, Aslam S, Aljaghwani A. Bacterial vaginosis in pregnancy: prevalence and outcomes in a tertiary care hospital. Afr J Reprod Health. 2021;25(1):49–55. doi: 10.29063/ajrh2021/v25i1.6
  15. Morris MC, Rogers PA, Kinghorn GR. Is bacterial vaginosis a sexually transmitted infection? Sex Transm Infect. 2001;77(1):63–68. doi: 10.1136/sti.77.1.63
  16. Gong Z, Luna Y, Yu P, et al. Lactobacilli inactivate Chlamydia trachomatis through lactic acid but not H2O2. PLoS One. 2014;9(9). doi: 10.1371/journal.pone.0107758
  17. Graver MA, Wade JJ. The role of acidification in the inhibition of Neisseria gonorrhoeae by vaginal lactobacilli during anaerobic growth. Ann Clin Microbiol Antimicrob. 2011;10:8. doi: 10.1186/1476-0711-10-8
  18. Conti C, Malacrino C, Mastromarino P. Inhibition of herpes simplex virus type 2 by vaginal lactobacilli. J Physiol Pharmacol. 2009;60(Suppl 6):19–26.
  19. Aldunate M, Tyssen D, Johnson A, et al. Vaginal concentrations of lactic acid potently inactivate HIV. J Antimicrob Chemother. 2013;68(9):2015–2025. doi: 10.1093/jac/dkt156
  20. Valore EV, Park CH, Igreti SL, et al. Antimicrobial components of vaginal fluid. Am J Obstet Gynecol. 2002;187(3):561–568. doi: 10.1067/mob.2002.125280
  21. Boskey ER, Cone RA, Whaley KJ, et al. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Human Reproduction. 2001;16(9):1809–1813. doi: 10.1093/humrep/16.9.1809
  22. Witkin SS, Mendes-Soares H, Linhares IM, et al. Influence of vaginal bacteria and D- and L-lactic acid isomers on vaginal extracellular matrix metalloproteinase inducer: implications for protection against upper genital tract infections. mBio. 2013;4(4):e00460–13. doi: 10.1128/mBio.00460-13
  23. Hearps AC, Tyssen D, Srbinovski D, et al. Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition. Mucosal Immunol. 2017;10(6):1480–1490. doi: 10.1038/mi.2017.27
  24. Andersch B, Forssman L, Lincoln K, et al. Treatment of bacterial vaginosis with an acid cream: a comparison between the effect of lactate-gel and metronidazole. Gynecol Obstet Invest. 1986;21(1):19–25. doi: 10.1159/000298923
  25. Andersch B, Lindell D, Dahlén I, Brandberg A. Bacterial vaginosis and the effect of intermittent prophylactic treatment with an acid lactate gel. Gynecol Obstet Invest. 1990;30(2):114–119. doi: 10.1159/000293230
  26. Armstrong-Buisseret L, Brittain C, et al. Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT. Health Technol Assess. 2022;26(2):1–170. doi: 10.3310/ZZKH4176
  27. Amatya R, Bhattarai S, Mandal PK, et al. Urinary tract infection in vaginitis: a condition often overlooked. Nepal Med Coll J. 2013;15(1):65–67.
  28. Gottschick C, Deng ZL, Vital M, et al. The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. Microbiome. 2017;5(1):99. doi: 10.1186/s40168-017-0305-3
  29. Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol. 2000;151(12):1194–1205. doi: 10.1093/oxfordjournals.aje.a010170
  30. Ahmed H, Davies F, Francis N, et al. Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: systematic review and meta-analysis of randomised trials. BMJ Open. 2017;7(5). doi: 10.1136/bmjopen-2016-015233
  31. Foxman B, Barlow R, D’Arcy H, et al. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000;10(8):509–515. doi: 10.1016/s1047-2797(00)00072-7
  32. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon. 2003;49(2):71–82. doi: 10.1067/mda.2003.8
  33. Storme O., Tirán Saucedo J., Garcia-Mora A., et al. Risk factors and predisposing conditions for urinary tract infection. Ther Adv Urol. 2019;11:19–28. doi: 10.1177/1756287218814382
  34. Brannon JR, Dunigan TL, Beebout CJ, et al. Invasion of vaginal epithelial cells by uropathogenic Escherichia coli. Nat Commun. 2020;11(1). doi: 10.1038/s41467-020-16627-5
  35. O’Brien VP, Lewis AL, Gilbert NM. Bladder exposure to gardnerella activates host pathways necessary for Escherichia coli recurrent uti. Front Cell Infect Microbiol. 2021;11. doi: 10.3389/fcimb.2021.788229
  36. Rosen DA, Hooton TM, Stamm WE, et al. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med. 2007;4(12). doi: 10.1371/journal.pmed.0040329
  37. Gilbert NM, O’Brien VP, Lewis AL. Transient microbiota exposures activate dormant Escherichia coli infection in the bladder and drive severe outcomes of recurrent disease. PLoS Pathog. 2017;13(3). doi: 10.1371/journal.ppat.1006238
  38. Diebold R, Schopf B, Stammer H, et al. Vaginal treatment with lactic acid gel delays relapses in recurrent urinary tract infections: results from an open, multicentre observational study. Arch Gynecol Obstet. 2021;304(2):409–417. doi: 10.1007/s00404-021-06040-8
  39. Swidsinski A, Loening-Baucke V, Mendling W, et al. Positive effects of local therapy with a vaginal lactic acid gel on dysuria and E. coli bacteriuria question our current views on recurrent cystitis. Arch Gynecol Obstet. 2012;285(6):1619–1625. doi: 10.1007/s00404-011-2196-z

Supplementary files

There are no supplementary files to display.


Copyright (c) 2023 Eсо-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 66759 от 08.08.2016 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия Эл № 77 - 6389 от 15.07.2002 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies